Q-Immune provides a platform that maps real‑time protein interaction networks in living cells using its Quantitative Multiplex co‑Immunoprecipitation (QMI) technology. By decoding dynamic signalosome profiles and applying AI‑driven analytics, it identifies biosignatures that predict safety and efficacy, enabling biopharma companies to engineer cell therapies with built‑in safety controls and more predictable clinical performance.
Funding
Funding not disclosed
Founders
Product
Problem
Current cell therapy development, such as CAR‑T, relies on static ‘omics’ measurements that capture only snapshots of cellular activity. This approach misses the dynamic protein interaction networks that drive cell behavior, leading to unpredictable efficacy and severe toxicities that limit broader clinical use.
Solution
Q‑Immune offers a platform that maps real‑time protein interaction networks inside living cells using its Quantitative Multiplex co‑Immunoprecipitation (QMI) technology. By decoding these dynamic signalosome profiles, the platform identifies biosignatures predictive of safety and performance, enabling the engineering of cell therapies with built‑in safety controls. Integrated advanced AI analyzes the multiplex data to guide iterative cycles of discovery, optimization, and translation, turning complex cell therapies into predictable, bioengineered products suitable for first‑line treatment.
Target Audience
Primary customers are biopharmaceutical companies and research organizations developing cell‑based therapeutics, particularly those focused on CAR‑T and other advanced immunotherapies.
Features
- Quantitative Multiplex co‑Immunoprecipitation (QMI) captures real‑time protein‑protein interactions in living cells
- Patented signalosome profiling reveals dynamic network assembly and changes missed by traditional static assays
- AI‑driven analytics extract predictive biosignatures for toxicity and therapeutic efficacy
- End‑to‑end workflow: native network mapping, biosignature decoding, cell programming, and in vitro/in vivo testing
- Platform supports continuous optimization cycles for rapid translation of cell therapies